Damora Therapeutics, Inc. (DMRA) — Cash Flow-to-Debt Ratio
Damora Therapeutics, Inc. (DMRA) has a Cash Flow-to-Debt Ratio of 0.03x as of December 2025, meaning its operating cash flow of $566.00K could theoretically repay 0% of its total liabilities ($20.15 Million) in one year. See DMRA free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Damora Therapeutics, Inc. Cash Flow-to-Debt Ratio (2018–2025)
Historical debt coverage capacity for Damora Therapeutics, Inc. across 8 annual periods. Also explore Damora Therapeutics, Inc. (DMRA) net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Damora Therapeutics, Inc. (2018–2025)
Year-by-year debt coverage analysis for Damora Therapeutics, Inc.. For market capitalisation and broader financial context, see Damora Therapeutics, Inc. stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.33x | $-6.73 Million | $20.15 Million | ▲ +95.2% |
| 2024 | -7.00x | $-18.62 Million | $2.66 Million | ▼ -11.8% |
| 2023 | -6.26x | $-36.91 Million | $5.90 Million | ▼ -66.7% |
| 2022 | -3.75x | $-42.93 Million | $11.44 Million | ▲ +64.2% |
| 2021 | -10.48x | $-52.31 Million | $4.99 Million | ▼ -67.5% |
| 2020 | -6.26x | $-38.20 Million | $6.11 Million | ▼ -163.4% |
| 2019 | -2.37x | $-19.33 Million | $8.14 Million | ▲ +22.9% |
| 2018 | -3.08x | $-13.69 Million | $4.44 Million | — |